To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.
Additional recommended knowledge
Alfuzosin is marketed by Sanofi Aventis under the brand name Uroxatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.
The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alfuzosin". A list of authors is available in Wikipedia.|